Teva Pharma (TEVA) PT Raised to $22 at RBC Capital
Tweet
Share
E-mail
Get Alerts TEVA Hot Sheet
Price: $37.09 +2.04%
Rating Summary:
18 Buy, 21 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 3 | Down: 5 | New: 34
Rating Summary:
18 Buy, 21 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 3 | Down: 5 | New: 34
Join SI Premium – FREE
RBC Capital analyst Randall Stanicky raised the price target on Teva Pharma (NYSE: TEVA) to $22.00 (from $19.00) while maintaining a Sector Perform rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Teva prices $4.9B senior notes offering to refinance debt
- Adobe (ADBE) PT Raised to $255 at UBS Following Q3 Results
- Restoration Hardware (RH) PT Lowered to $81 at BNP Paribas Exane
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
RBC CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
